Xoma (US) LLC

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum

Phase 2
Completed
Conditions
Pyoderma Gangrenosum
Interventions
Drug: gevokizumab
First Posted Date
2013-06-20
Last Posted Date
2016-02-03
Lead Sponsor
XOMA (US) LLC
Target Recruit Count
8
Registration Number
NCT01882504

Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment

First Posted Date
2012-12-11
Last Posted Date
2016-07-12
Lead Sponsor
XOMA (US) LLC
Target Recruit Count
281
Registration Number
NCT01747538

Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis

First Posted Date
2012-09-12
Last Posted Date
2016-04-08
Lead Sponsor
XOMA (US) LLC
Target Recruit Count
200
Registration Number
NCT01684345

Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand

Phase 2
Completed
Conditions
Osteoarthritis
Interventions
Drug: Placebo
Drug: gevokizumab
First Posted Date
2012-09-11
Last Posted Date
2014-03-04
Lead Sponsor
XOMA (US) LLC
Target Recruit Count
87
Registration Number
NCT01683396

Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris

Phase 2
Completed
Conditions
Acne Vulgaris
Interventions
Drug: Placebo
Drug: gevokizumab
First Posted Date
2011-12-26
Last Posted Date
2014-03-04
Lead Sponsor
XOMA (US) LLC
Target Recruit Count
127
Registration Number
NCT01498874

Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes Mellitus

Phase 2
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: XOMA 052
Drug: Placebo
First Posted Date
2010-06-16
Last Posted Date
2012-05-16
Lead Sponsor
XOMA (US) LLC
Target Recruit Count
76
Registration Number
NCT01144975

Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy

Phase 2
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Placebo
Drug: XOMA 052
First Posted Date
2010-02-10
Last Posted Date
2011-10-04
Lead Sponsor
XOMA (US) LLC
Target Recruit Count
421
Registration Number
NCT01066715

Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 Diabetes

Phase 2
Completed
Conditions
Type 1 Diabetes
Interventions
Drug: Xoma 052
Drug: Placebo
First Posted Date
2009-10-20
Last Posted Date
2014-03-04
Lead Sponsor
XOMA (US) LLC
Target Recruit Count
22
Registration Number
NCT00998699

Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis

Phase 2
Suspended
Conditions
Rheumatoid Arthritis
Interventions
Drug: Placebo
Drug: XOMA 052
First Posted Date
2008-10-22
Last Posted Date
2015-12-29
Lead Sponsor
XOMA (US) LLC
Target Recruit Count
18
Registration Number
NCT00777816

Single-dose, Dose-escalation Study of Safety, PK, and Preliminary Efficacy of XOMA 052 in Type 2 Diabetes Mellitus

Phase 1
Completed
Conditions
Type 2 Diabetes
Interventions
Drug: XOMA 052
Drug: Placebo
First Posted Date
2007-10-10
Last Posted Date
2010-05-04
Lead Sponsor
XOMA (US) LLC
Target Recruit Count
36
Registration Number
NCT00541983
Locations
🇨🇭

Covance Clinical Research (formerly Swiss Pharma Contract), Allschwil, Switzerland

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy